- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/08 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
Patent holdings for IPC class C07D 215/08
Total number of patents in this class: 122
10-year publication summary
9
|
8
|
11
|
7
|
7
|
10
|
8
|
3
|
5
|
1
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bayer AG | 3323 |
7 |
Sanofi | 4036 |
6 |
Conopco, Inc. | 4994 |
4 |
Sumitomo Chemical Company, Limited | 9031 |
4 |
Lead Pharma Holding B.V. | 20 |
4 |
Bristol-myers Squibb Company | 4879 |
3 |
F. Hoffmann-La Roche AG | 7934 |
3 |
Merck Sharp & Dohme Corp. | 2200 |
3 |
Board of Regents, The University of Texas System | 5763 |
3 |
Cytokinetics, Inc. | 273 |
3 |
Unilever PLC | 3214 |
2 |
Unilever N.V. | 3121 |
2 |
President and Fellows of Harvard College | 5964 |
2 |
Northwestern University | 3374 |
2 |
Astex Therapeutics Limited | 237 |
2 |
Fondazione Istituto Italiano di Tecnologia | 578 |
2 |
Indiana University Research and Technology Corporation | 795 |
2 |
Japan Tobacco Inc. | 3580 |
2 |
Mitsubishi Tanabe Pharma Corporation | 579 |
2 |
SABIC Global Technologies B.V. | 4326 |
2 |
Other owners | 62 |